Sugi Predict

Sugi Predict / Compounds / SCHEMBL1380341

SCHEMBL1380341

SCHEMBL1380341

O=C(NC(F)(F)F)c1ccn[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 7/20 0.53
▸ RAB9A P51151 6/20 0.53
▸ NPC1 O15118 5/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ CDK2 P24941 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ HCAR2 Q8TDS4 1/20 0.52
▸ KMT2A Q03164 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ NAMPT P43490 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ HDAC3 O15379 1/20 0.46
▸ HDAC4 P56524 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC7 Q8WUI4 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20812638 0.81 ALOX15 (0.53) ALOX15RAB9ANPC1SMN1; SMN2CDK2
SCHEMBL28023283 0.78 — —
SCHEMBL13373395 0.76 ALOX15 (0.47) ALOX15RAB9ANPC1SMN1; SMN2CDK2
SCHEMBL29492415 0.75 ALOX15 (0.46) ALOX15RAB9ANPC1SMN1; SMN2CDK2
SCHEMBL1577007 0.75 — —
SCHEMBL298545 0.75 — —
SCHEMBL10719763 0.73 HCAR2 (0.61) ALOX15RAB9ANPC1SMN1; SMN2CDK2
SCHEMBL30767832 0.72 RAB9A (0.54) ALOX15RAB9ANPC1SMN1; SMN2CDK2
Trifluoroacetic Acid SCHEMBL4712611 0.72 HCAR2 (0.77) ALOX15RAB9ANPC1SMN1; SMN2CDK2
SCHEMBL3862510 0.71 PKM (0.44) ALOX15RAB9ANPC1SMN1; SMN2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11999699-B2 Substituted pyrazole amides Grünenthal GmbH (DE) 2024-06-04 — — US claimed
EP-4355733-A1 SUBSTITUTED PYRAZOLE AMIDES Grünenthal GmbH (DE) 2024-04-24 — — EP claimed
EP-4149945-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2023-03-22 — — EP claimed
US-20230025025-A1 SUBSTITUTED PYRAZOLE AMIDES GRUENENTHAL GMBH (DE) 2023-01-26 — — US claimed
WO-2022263498-A1 SUBSTITUTED PYRAZOLE AMIDES Grünenthal GmbH (DE) 2022-12-22 — — WO claimed
WO-2021229302-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2021-11-18 — — WO claimed
JP-4828073-B2 — — 2011-11-30 — — JP claimed
EP-1265850-A2 INSECTICIDAL ANTHRANILAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2002-12-18 — — EP claimed
WO-2001070671-A2 INSECTICIDAL ANTHRANILAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2001-09-27 — — WO claimed
US-20250236608-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-07-24 — — US disclosed
WO-2025108865-A1 HERBICIDAL COMPOSITIONS BAYER AKTIENGESELLSCHAFT (DE) 2025-05-30 — — WO disclosed
US-20240252473-A1 Sulfoximines as inhibitors of NaV1.8 GRUENENTHAL GMBH (DE) 2024-08-01 — — US disclosed
EP-4385979-A1 MULTICYCLIC INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2024-06-19 — — EP disclosed
US-11999699-B2 Substituted pyrazole amides Grünenthal GmbH (DE) 2024-06-04 — — US disclosed
EP-1460996-A4 NOVEL-N-4-(1H-IMIDAZOL-1-YL)-2-FLUOROPHENYL]-3-(TRIFLUOROMETHYL)-1-H-PYRAZOLE-5-CARBOXAMIDES AS FACTOR XA BRISTOL MYERS SQUIBB CO (US) 2005-11-16 — — EP disclosed
EP-1460996-A2 NOVEL-N-4-(1H-IMIDAZOL-1-YL)-2-FLUOROPHENYL]-3-(TRIFLUOROMETHYL)-1-H-PYRAZOLE-5-CARBOXAMIDES AS FACTOR XA Bristol-Myers Squibb Company (US) 2004-09-29 — — EP disclosed
US-20030229050-A1 Insecticidal anthranilamides FMC CORPORATION 2003-12-11 — — US disclosed
WO-2003047517-A2 NOVEL-N-[4-(1H-IMIDAZOL-1-YL)-2-FLUOROPHENYL]-3-(TRIFLUOROMETHYL)-1-H-PYRAZOLE-5-CARBOXAMIDES AS FACTOR XA BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-12 — — WO disclosed
EP-1265850-A2 INSECTICIDAL ANTHRANILAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2002-12-18 — — EP disclosed
WO-2001070671-A2 INSECTICIDAL ANTHRANILAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2001-09-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999699-B2 Substituted pyrazole amides SCN8A, SCN1A, SCN7A ALOX15 2368/4885RAB9A 1165/4885NPC1 2076/4885
US-20030229050-A1 Insecticidal anthranilamides ANTXR2, NIT2, CYB5R3 ALOX15 1649/4885RAB9A 304/4885NPC1 3299/4885
US-20250236608-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 ALOX15 4747/4885RAB9A 446/4885NPC1 1417/4885
US-20240252473-A1 Sulfoximines as inhibitors of NaV1.8 SCN8A, SCN10A, SCN7A ALOX15 1083/4885RAB9A 2096/4885NPC1 4661/4885
US-20230025025-A1 SUBSTITUTED PYRAZOLE AMIDES SCN8A, SCN1A, SCN7A ALOX15 2368/4885RAB9A 1165/4885NPC1 2076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.